Overview

Neoadjuvant GW572016 to Treat Breast Cancer

Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
We want to learn whether GW572016 is effective in breast cancers that have HER2.
Phase:
Phase 2
Details
Lead Sponsor:
Baylor Breast Care Center
Collaborator:
GlaxoSmithKline
Treatments:
Lapatinib